Table 1.
Demographics and clinical profile.
| N | Responder | Remitter | Non-Responder | p | V | |||
|---|---|---|---|---|---|---|---|---|
| Male sex | (%) | 21 (42.9) | 6 (66.7) | 2 (25.0) | 13 (40.6) | 0.229 | 0.26 | |
| Female sex | (%) | 28 (57.1) | 3 (33.3) | 6 (75.0) | 19 (59.4) | |||
| Mean age, in years | 50.02 | 53.11 | 42.88 | 50.94 | 0.336 | 0.00 | ||
| Occupation | 0.250 | 0.32 | ||||||
| Employed | 11 (22.4) | 2 (22.2) | 2 (25.0) | 7 (21.9) | ||||
| Unemployed | 27 (55.1) | 7 (77.8) | 3 (37.5) | 18 (56.2) | ||||
| Pension | 10 (20.4) | 0 (0) | 3 (37.5) | 7 (21.9) | ||||
| Seasonal work | 1 (2.0) | 0 (0) | 0 (0) | 1 (3.1) | ||||
| Education | 0.252 | 0.26 | ||||||
| Elementary or lower | 2 (4.1) | 0 (0) | 1 (12.5) | 1 (3.1) | ||||
| Vocational | 5 (10.2) | 2 (22.2) | 1 (12.5) | 2 (6.3) | ||||
| Secondary | 18 (36.7) | 1 (11.1) | 3 (37.5) | 14 (43.8) | ||||
| Higher | 24 (49.0) | 6 (66.7) | 3 (37.5) | 15 (46.9) | ||||
| BMI | 27.92 (5.67) | 28.00 (4.64) | 26.50 (4.72) | 28.25 (6.21) | 0.613 | 0.02 | ||
| Ketamine treatment for: | ||||||||
| MDD | 35 (71.4) | 8 (88.9) | 5 (62.5) | 22 (68.8) | 0.475 | 0.19 | ||
| BP | 14 (28.6) | 2 (11.1) | 5 (37.5) | 7 (31.2) | 0.485 | 0.18 | ||
| Comorbidity | 0.104 | 0.31 | ||||||
| 1 | 21 (42.9) | 6 (66.7) | 2 (25.0) | 13 (40.6) | ||||
| 2 | 10 (20.4) | 2 (22.2) | 1 (12.5) | 7 (21.9) | ||||
| 3 | 4 (8.2) | 1 (11.1) | 2 (25.0) | 1 (3.1) | ||||
| Arterial hypertension | 16 (32.7) | 6 (66.7) | 3 (37.5) | 7 (21.9) | 0.037 | 0.37 | ||
| BP | 4 (8.2) | 1 (11.1) | 2 (25.0) | 1 (3.1) | 0.052 | 0.66 | ||
| MDD | 12 (24.5) | 5 (55.6) | 1 (12.5) | 6 (18.8) | 0.177 | 0.33 | ||
| Diabetes mellitus | 3 (6.1) | 1 (11.1) | 2 (25.0) | 0 (0) | 0.021 | 0.39 | ||
| Hyperlipidaemia | 9 (18.4) | 3 (33.3) | 1 (12.5) | 5 (15.6) | 0.545 | 0.19 | ||
| Post-stroke | 3 (6.1) | 1 (11.1) | 0 (0) | 2 (6.3) | 0.731 | 0.14 | ||
| Post-myocardial infarction | 0 (0) | 0 (0) | 0 (0) | 0 (0) | - | - | ||
| Epilepsy | 6 (12.2) | 0 (0) | 3 (37.5) | 3 (9.4) | 0.060 | 0.36 | ||
| Other | 16 (32.7) | 2 (22.2) | 1 (12.5) | 13 (40.6) | 0.330 | 0.24 | ||
| Coexisting treatment | ||||||||
| TCA | 8 (16.3) | 1 (11.1) | 1 (13.5) | 6 (18.8) | 1.000 | 0.09 | ||
| Clomipramine | 4 (8.2) | 0 (0) | 1 (12.5) | 3 (9.4) | 0.789 | 0.15 | ||
| Amitriptyline | 4 (8.2) | 1 (11.1) | 0 (0) | 3 (9.4) | 1.000 | 0.13 | ||
| SSRI total | 23 (46.9) | 5 (55.6) | 2 (25.0) | 16 (50.0) | 0.413 | 0.20 | ||
| Fluvoxamine | 1 (2.0) | 0 (0) | 0 (0) | 1 (3.1) | 1.000 | 0.11 | ||
| Paroxetine | 5(10.2) | 1 (11.1) | 0 (0) | 4 (12.5) | 0.813 | 0.15 | ||
| Fluoxetine | 8 (16.3) | 2 (22.2) | 0 (0) | 6 (18.8) | 0.534 | 0.20 | ||
| Sertraline | 3 (6.1) | 1 (11.1) | 0 (0) | 2 (6.3) | 0.731 | 0.14 | ||
| Citalopram | 4 (8.2) | 0 (0) | 2 (25.0) | 2 (6.3) | 0.179 | 0.29 | ||
| Escitalopram | 2 (4.1) | 1 (11.1) | 0 (0) | 1 (3.1) | 0.578 | 0.18 | ||
| SNRI total | 11 (22.4) | 2 (22.2) | 2 (25.0) | 7 (21.9) | 1.000 | 0.03 | ||
| Venlafaxine | 8 (16.3) | 1 (11.1) | 1 (12.5) | 6 (18.8) | 1.000 | 0.10 | ||
| Duloxetine | 3 (6.1) | 1 (11.1) | 1 (12.5) | 1 (3.1) | 0.273 | 0.17 | ||
| Other ADTs: | 0.749 | 0.14 | ||||||
| 1 | 15 (30.6) | 4 (44.4) | 2 (25.0) | 9 (28.1) | ||||
| 2 | 3 (6.1) | 0 (0) | 1 (12.5) | 2 (6.3) | ||||
| Mirtazapine | 9 (18.4) | 2 (22.2) | 1 (12.5) | 6 (18.8) | 1.000 | 0.08 | ||
| Mianserin | 3 (6.1) | 1 (11.1) | 0 (0) | 2 (6.3) | 0.731 | 0.14 | ||
| Trazodone | 4 (8.2) | 1 (11.1) | 1 (12.5) | 2 (6.3) | 0.432 | 0.10 | ||
| Bupropion | 3 (6.1) | 0 (0) | 1 (12.5) | 2 (6.3) | 0.488 | 0.15 | ||
| Vortioxetine | 2 (4.1) | 0 (0) | 1 (12.5) | 1 (3.1) | 0.333 | 0.20 | ||
| Antipsychotics | 0.806 | 0.15 | ||||||
| 1 | 12 (24.5) | 2 (22.2) | 1 (12.5) | 9 (28.1) | ||||
| 2 | 5 (10.2) | 0 (0) | 1 (12.5) | 4 (12.5) | ||||
| Aripiprazole | 6 (12.2) | 0 (0) | 1 (12.5) | 5 (15.6) | 0.685 | 0.18 | ||
| Quetiapine | 10 (20.4) | 1 (11.1) | 1 (12.5) | 8 (25.0) | 0.668 | 0.16 | ||
| Olanzapine | 5 (10.2) | 1 (11.1) | 1 (12.5) | 3 (9.4) | 1.000 | 0.04 | ||
| Risperidone | 1 (2.0) | 0 (0) | 0 (0) | 1 (3.1) | 1.000 | 0.11 | ||
| Mood stabilisers | 0.348 | 0.29 | ||||||
| 1 | 15 (30.6) | 2 (22.2) | 4 (50.0) | 9 (28.1) | ||||
| 2 | 6 (12.2) | 1 (11.1) | 0 (0) | 5 (15.6) | ||||
| 3 | 1 (2.0) | 0 (0) | 1 (12.5) | 0 (0) | ||||
| Lithium | 5 (10.2) | 0 (0) | 1 (12,5) | 4 (12.5) | 0.643 | 0.16 | ||
| Valproate | 9 (18.4) | 2 (22.2) | 3 (37.5) | 4 (12.5) | 0.160 | 0.24 | ||
| Lamotrigine | 7 (14.3) | 1 (11.1) | 1 (12.5) | 5 (15.6) | 1.000 | 0.05 | ||
N, sample size; p, probability value; V, Cramer’s V; MDD, major depressive disorder; BP, bipolar disorder; TCA, other tricyclic antidepressant; SSRI, selective serotonin reuptake inhibitor; SNRI, selective serotonin-noradrenaline reuptake inhibitors; ADTs, antidepressants; BMI, body mass index.